Report / Paper metadata
Dapagliflozin does not impair LDL catabolism and induces a shift towards a closer to normal VLDL(1)/VLDL(2) catabolism in individuals with type 2 diabetes: a randomised in vivo kinetic study.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata